-
Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy. Circulation (IF 35.5) Pub Date : 2024-12-05 Joshua K Meisner,Aaron Renberg,Eric D Smith,Yao-Chang Tsan,Brynn Elder,Abbey Bullard,Owen Merritt,Sean L Zheng,Neal Lakdawala,Anjali Owens,Thomas D Ryan,Erin M Miller,Joseph Rossano,Kimberly Y Lin,Brian Claggett,Euan Ashley,Michelle Michels,Rachel Lampert,John C Stendahl,Dominic Abrahams,Christopher Semsarian,Victoria N Parikh,Matthew Wheeler,Jodie Ingles,Sharlene M Day,Sara Saberi,Mark W Russell,Michael
BACKGROUND Classically, hypertrophic cardiomyopathy (HCM) has been viewed as a single-gene (monogenic) disease caused by pathogenic variants in sarcomere genes. Pathogenic sarcomere variants are individually rare and convey high risk for developing HCM (highly penetrant). Recently, important polygenic contributions have also been characterized. Low penetrance sarcomere variants (LowSVs) at intermediate
-
Sickle Trait and Alpha Thalassemia Increase NOS-Dependent Vasodilation of Human Arteries Through Disruption of Endothelial Hemoglobin-eNOS Interactions. Circulation (IF 35.5) Pub Date : 2024-12-05 Steven D Brooks,A Parker Ruhl,Xianke Zeng,Phillip Cruz,Sergio A Hassan,Olena Kamenyeva,Md Abdul Hakim,Lauryn A Ridley,Bianca M Nagata,Juraj Kabat,Sundar Ganesan,Rachel L Smith,Mary Jackson,Jessica Nino de Rivera,Alison J McLure,Jarrett M Jackson,Robert O Emeh,Naomi Tesfuzigta,Kyeisha Laurence,Stacy Joyce,Christina Yek,Sophana Chea,Derron A Alves,Brant E Isakson,Jessica Manning,Jeremy L Davis,Hans C
BACKGROUND Severe malaria is associated with impaired nitric oxide (NO) synthase (NOS)-dependent vasodilation, and reversal of this deficit improves survival in murine models. Malaria might have selected for genetic polymorphisms that increase endothelial NO signaling and now contribute to heterogeneity in vascular function among humans. One protein potentially selected for is alpha globin, which,
-
Diagnostic and Prognostic Performance of High-Sensitivity Cardiac Troponin T vs I J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-12-04 Luca Koechlin, Jasper Boeddinghaus, Dimitrios Doudesis, Pedro Lopez-Ayala, Tobias Zimmermann, Klara Rumora, Jeanne du Fay de Lavallaz, Ziwen Li, Kuan Ken Lee, Andrew R. Chapman, Karin Wildi, Danielle M. Gualandro, Muntadher Al Karam, Maria Rubini Giménez, Gabrielle Huré, Òscar Miró, Zoe Klein, Paolo Bima, Desiree Wussler, Michael Christ, Christian Mueller
Section snippets Study designThis was a secondary analysis of the APACE (Advantageous Predictors of Acute Coronary Syndromes Evaluation; NCT00470587) study.7 For this analysis, we excluded patients with ST-segment elevation MI, patients in whom the diagnosis remained unclear even after final adjudication and had at least 1 elevated concentration of hs-cTnT/I, and patients with missing hs-cTnT or hs-cTnI
-
The Patient Behind the Doctor J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-12-04 Denisa Metani
Section snippets Funding Support and Author DisclosuresThe author has reported that she has no relationships relevant to the contents of this paper to disclose.
-
The Coming AI Revolution in Clinical Trials J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-12-04 Sneha S. Jain, Ashish Sarraju, Nigam H. Shah, Kevin A. Schulman, Euan A. Ashley, Robert A. Harrington, Kenneth W. Mahaffey
Section snippets Digital Strategy and Data InfrastructureCurrent systems for data storage and analysis are siloed, limiting the potential for AI to function efficiently across data networks. Without interoperable data systems, even the most advanced AI tools will struggle to deliver real impact. We need a unified data strategy—how we manage, integrate, and safeguard data across platforms—focused on
-
Dynamic Trends and Practice Patterns in Femoropopliteal Revascularization From 2016 Through 2023 J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-12-04 Joseph M. Kim, Siling Li, Yang Song, Robert W. Yeh, Eric A. Secemsky
Section snippets Data sourcesThe study included all Medicare fee-for-service beneficiaries aged ≥66 years who underwent femoropopliteal revascularization by International Classification of Diseases–10th Revision codes between January 1, 2016, and December 31, 2023. Patient comorbidities were identified using the Chronic Conditions Warehouse data, and procedural data were identified using claims codes
-
In the Wake of OCEANIC-AF, Is Equipoise Regarding Factor XI Inhibition Still Afloat? J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-12-04 C. Michael Gibson
Although factor Xa inhibitors reduce intracranial hemorrhage vs vitamin K antagonists in atrial fibrillation (AF),1 concerns regarding nonintracranial bleeding have led to the development of factor XI/XIa inhibitors, which offer the promise of uncoupling pathologic thrombosis from normal hemostasis. Although phase 2 and 3 studies support the safety of factor XI/XIa inhibition in a variety of settings
-
The Importance of Growing the Next Generation of Global Cardiovascular Leaders J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-12-04 Cathleen Biga, Wael Al Mahmeed
No Abstract
-
Digital Health Technologies for Cardiometabolic Disease and Diabetes: A Perspective From the U.S. Food and Drug Administration J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-12-04 Haider J. Warraich, Bray Patrick-Lake, Anindita Saha, Leeda Rashid, Vinay Pai, Ali Abbasi, Matthew C. Diamond, Troy Tazbaz, Robert M. Califf
Section snippets Overview of DHT RegulationDHTs that meet the definition of a medical device are regulated by the FDA, which applies regulatory controls and marketing pathways based on the intended use and potential risk of the device (Figure 1). Devices are classified from Class 1 with the lowest risk (eg, a toothbrush, Digital Visual Acuity Test), Class 2 with intermediate risk (eg, CGMs, WellDoc’s
-
BHLH Transcription Factor TCF21 Inhibits Myofibroblast Formation and Cardiac Fibrosis. Circ. Res. (IF 16.5) Pub Date : 2024-12-04 Anne Katrine Z Johansen,Rajesh K Kasam,Ronald J Vagnozzi,Suh-Chin J Lin,Jose G Gomez-Arroyo,Adenike Shittu,Stephanie L K Bowers,Yasuhide Kuwabara,Kelly M Grimes,Kathrynne Warrick,Michelle A Sargent,Tanya A Baldwin,Susan E Quaggin,Artem Barski,Jeffery D Molkentin
BACKGROUND TCF21 (transcription factor 21) is a bHLH (basic helix-loop-helix) protein required for the developmental specification of cardiac fibroblasts (CFs) from epicardial progenitor cells that surround the embryonic heart. In the adult heart, TCF21 is expressed in tissue-resident fibroblasts and is downregulated in response to injury or stimuli leading to myofibroblast differentiation. These findings
-
A Vaccine Against Fibroblast Activation Protein Improves Murine Cardiac Fibrosis by Preventing the Accumulation of Myofibroblasts. Circ. Res. (IF 16.5) Pub Date : 2024-12-04 Shota Yoshida,Hiroki Hayashi,Takuro Kawahara,Shunsuke Katsuki,Mitsukuni Kimura,Rissei Hino,Jiao Sun,Ryo Nakamaru,Akiko Tenma,Masayoshi Toyoura,Satoshi Baba,Munehisa Shimamura,Tomohiro Katsuya,Ryuichi Morishita,Hiromi Rakugi,Tetsuya Matoba,Hironori Nakagami
BACKGROUND Myofibroblasts are primary cells involved in chronic response-induced cardiac fibrosis. Fibroblast activation protein (FAP) is a relatively specific marker of activated myofibroblasts and a potential target molecule. This study aimed to clarify whether a vaccine targeting FAP could eliminate myofibroblasts in chronic cardiac stress model mice and reduce cardiac fibrosis. METHODS We coadministered
-
Autoimmune-Like Mechanism in Heart Failure Enables Preventive Vaccine Therapy. Circ. Res. (IF 16.5) Pub Date : 2024-12-04 Elisa Martini,Marco Cremonesi,Arianna Felicetta,Simone Serio,Simone Puccio,Erica Pelamatti,Jasper J P van Beek,Vasiliki Papadopoulou,Chiara Catalano,Francesca Fanuele,Desirée Giuliano,Gianluca Basso,Cecilia Assunta Bonfiglio,Cristina Panico,Marco Vacchiano,Pierluigi Carullo,Laura Papa,Carla D'Andrea,Naz Tuzger,Sergio Marchini,Paola Magistroni,Silvia Deaglio,Antonio Amoroso,Enrico Lugli,Gianluigi Condorelli
BACKGROUND Heart failure (HF) is strongly associated with inflammation. In pressure overload (PO)-induced HF, cardiac stress triggers adaptive immunity, ablation, or inhibition, which blocks disease progression. We hypothesized that PO-HF might fulfill the often-used criteria of autoimmunity: if so, the associated adaptive immune response would be not only necessary but also sufficient to induce HF;
-
GSK3β Deficiency Expands Obese Adipose Vasculature to Mitigate Metabolic Disorders. Circ. Res. (IF 16.5) Pub Date : 2024-12-04 Li Wang,Jiajia Li,Ping Tang,Dongliang Zhu,Lixin Tai,Yuan Wang,Tsukiko Miyata,James R Woodgett,Lijun Di
BACKGROUND Maintaining a well-developed vascular system alongside adipose tissue (AT) expansion significantly reduces the risk of metabolic complications. Although GSK3β (glycogen synthase kinase-3 beta) is known for its role in various cellular processes, its specific functions in AT and regulation of body homeostasis have not been reported. METHODS GSK3β-floxed and GSK3α-floxed mice were crossed
-
Aspirin for Secondary Prevention of Atherosclerosis-Evidence or Dogma? JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-04 John G F Cleland
-
Unfolding the Link Between Transthyretin Stability and Survival. JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-04 Anthony Angueira,Sarah A Abramowitz,Michael G Levin
-
Transthyretin Tetramer Destabilization and Increased Mortality in the General Population JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-04 Mette Christoffersen, Anders Møller Greve, Louise Stig Hornstrup, Ruth Frikke-Schmidt, Børge Grønne Nordestgaard, Anne Tybjærg-Hansen
ImportanceTransthyretin tetramer destabilization is the rate-limiting step in the development of transthyretin cardiac amyloidosis, an underrecognized contributor to mortality in older adults.ObjectiveTo test the hypothesis that transthyretin tetramer destabilization is associated with all-cause and cardiovascular mortality in the general population.Design, Setting, and ParticipantsIn this cohort study
-
Contents J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-12-02
Section snippets Major Bleeding and Mortality After Revascularization of Left Main Disease 2335Gennaro Giustino, Joseph F. Sabik III, Patrick W. Serruys, John D. Puskas, Dimitri Karmpaliotis, David E. Kandzari, Marie-Claude Morice, Michael Ragosta III, Zixuan Zhang, Ovidiu Dressler, Bjorn Redfors, Ori Ben-Yehuda, Samin K. Sharma, Arie Pieter Kappetein, Gregg W. StoneThe authors evaluated the incidence
-
Artificial intelligence and digital tools for design and execution of cardiovascular clinical trials Eur. Heart J. (IF 37.6) Pub Date : 2024-12-03 Jiun-Ruey Hu, John R Power, Faiez Zannad, Carolyn S P Lam
Recent advances have given rise to a spectrum of digital health technologies that have the potential to revolutionize the design and conduct of cardiovascular clinical trials. Advances in domain tasks such as automated diagnosis and classification, synthesis of high-volume data and latent data from adjacent modalities, patient discovery, telemedicine, remote monitoring, augmented reality, and in silico
-
-
Major Bleeding and Mortality After Revascularization of Left Main Disease J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-12-02 Gennaro Giustino, Joseph F. Sabik, Patrick W. Serruys, John D. Puskas, Dimitri Karmpaliotis, David E. Kandzari, Marie-Claude Morice, Michael Ragosta, Zixuan Zhang, Ovidiu Dressler, Bjorn Redfors, Ori Ben-Yehuda, Samin K. Sharma, Arie Pieter Kappetein, Gregg W. Stone
-
The Reducer Is a Novel, Safe, and Effective Therapy to Optimize the Management of Patients With Stable Angina J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-12-02 Shmuel Banai, Amir Lerman, Stefan Verheye
No Abstract
-
Optimizing Management of Stable Angina: Lifestyle Intervention as the Third Pillar J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-12-02 Iris A. de Koning, Tom Vromen, Joyce M. Heutinck, Hareld M.C. Kemps, Dick H.J. Thijssen
No Abstract
-
REPLY: Exercise-Based Cardiac Rehabilitation and Coronary Sinus Reducer in the Management of Stable Angina J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-12-02 Rocco A. Montone, Riccardo Rinaldi, Giuseppe Andò, Pasquale Perrone Filardi, Filippo Crea
No Abstract
-
Correction J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-12-02
Thompson A, Fleischmann KE, Smilowitz NR, de las Fuentes L, Mukherjee D, Aggarwal NR, Ahmad FS, Allen RB, Altin SE, Auerbach A, Berger JS, Chow B, Dakik HA, Eisenstein EL, Gerhard-Herman M, Ghadimi K, Kachulis B, Leclerc J, Lee CS, Macaulay TE, Mates G, Merli GJ, Parwani P, Poole JE, Rich MW, Ruetzler K, Stain SC, Sweitzer B, Talbot AW, Vallabhajosyula S, Whittle J, Williams KA Sr.
-
The cardio-oncologic burden of breast cancer: molecular mechanisms and importance of preclinical models Basic Res. Cardiol. (IF 7.5) Pub Date : 2024-12-02 J. Brauer, M. Tumani, N. Frey, L. H. Lehmann
Breast cancer, the most prevalent cancer affecting women worldwide, poses a significant cardio-oncological burden. Despite advancements in novel therapeutic strategies, anthracyclines, HER2 antagonists, and radiation remain the cornerstones of oncological treatment. However, each carries a risk of cardiotoxicity, though the molecular mechanisms underlying these adverse effects differ. Common mechanisms
-
Letter by Yang and Zhang Regarding Article, "Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial". Circulation (IF 35.5) Pub Date : 2024-12-02 Xinyue Yang,Zhiqiang Zhang
-
-
In Vivo Cardiovascular Molecular Imaging: Contributions to Precision Medicine and Drug Development. Circulation (IF 35.5) Pub Date : 2024-12-02 Jonathan R Lindner,Matteo Morello
Conventional forms of noninvasive cardiovascular imaging that evaluate morphology, function, flow, and metabolism play a vital role in individual treatment decisions, often based on guidelines. Innovations in molecular imaging have enhanced our ability to spatially quantify the expression of a wider array of disease-related proteins, genes, or cell types, or the activity of specific pathogenic pathways
-
Reply by Sandhu et al to Letter Regarding Article, "Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial". Circulation (IF 35.5) Pub Date : 2024-12-02 Alexander T Sandhu,John A Spertus,Paul A Heidenreich
-
Pitfalls of Choosing a Study End Point Including Cardiovascular Death in Comparative Clinical Trials. Circulation (IF 35.5) Pub Date : 2024-12-02 Stephanie Armbruster,Hicham Skali,Lee-Jen Wei
-
The prognostic value of the Dandel's index in patients undergoing tricuspid transcatheter edge‐to‐edge repair Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-12-02 Mohammad Kassar, Nicolas Brugger, Lukas Stolz, Muhammed Gerçek, Vera Fortmeier, Karl‐Patrik Kresoja, Jennifer von Stein, Benedikt Koell, Wolfgang Rottbauer, Bjoern Goebel, Paolo Denti, Paul Achouh, Tienush Rassaf, Manuel Barreiro‐Perez, Peter Boekstegers, Andreas Rück, Monika Zdanyte, Marianna Adamo, Flavien Vincent, Philipp Schlegel, Ralph‐Stephan von Bardeleben, Mirjam G. Wild, Stefan Toggweiler
-
Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: A pilot randomized controlled trial Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-12-02 Neil Keshvani, Syed Rizvi, Matthew W. Segar, James W. Miller, Juan David Coellar, Kershaw V. Patel, Bethany Roehm, W.H. Wilson Tang, Ambarish Pandey
AimsDiuretic resistance (DR) in heart failure (HF) is associated with worse outcomes. Furoscix®, a self‐administered subcutaneous (sc) furosemide injection administered via on‐body infusor, is approved for HF congestion relief. However, its efficacy in patients with DR post‐HF hospitalization remains unknown.Methods and resultsIn this open‐label pilot randomized controlled trial, 70 participants were
-
Midterm outcomes of patients with native heart recovery after Impella 5+ for cardiogenic shock Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-12-02 Marta Bandini, Nicoletta D'Ettore, Walter Iannotti, Tommaso Capobianco, Giulia Maj, Astrid Cardinale, Alina Gallo, Andrea Audo, Federico Pappalardo
-
Wearable Remote Patient Monitoring Devices: Ready for Prime Time? JACC Heart Fail. (IF 10.3) Pub Date : 2024-12-01 Sandip Zalawadiya,JoAnn Lindenfeld
-
Refining a Stratified Medicine Approach to Heart Failure: The Case for Targeting Uric Acid. JACC Heart Fail. (IF 10.3) Pub Date : 2024-12-01 W H Wilson Tang
-
Navigating The Complex Path From Monogenic to Polygenic Clinical Genetic Testing in Hypertrophic Cardiomyopathy. JACC Heart Fail. (IF 10.3) Pub Date : 2024-12-01 Roddy Walsh
-
Reply: Choosing the Appropriate Combination of Diuretics for Patients With Heart Failure and Congestion. JACC Heart Fail. (IF 10.3) Pub Date : 2024-12-01 Aharon Ronnie Abbo,Amit Gruber,Ina Volis,Doron Aronson,Oren Caspi
-
Choosing the Appropriate Combination of Diuretics for Patients With Heart Failure and Congestion. JACC Heart Fail. (IF 10.3) Pub Date : 2024-12-01 Edgar Francisco Carrizales-Sepúlveda,Alejandro Ordaz-Farías,Raymundo Vera-Pineda,Ramiro Flores-Ramírez
-
Artificial intelligence-derived electrocardiographic aging and risk of atrial fibrillation: a multi-national study. Eur. Heart J. (IF 37.6) Pub Date : 2024-11-29 Seunghoon Cho,Sujeong Eom,Daehoon Kim,Tae-Hoon Kim,Jae-Sun Uhm,Hui-Nam Pak,Moon-Hyoung Lee,Pil-Sung Yang,Eunjung Lee,Zachi Itzhak Attia,Paul Andrew Friedman,Seng Chan You,Hee Tae Yu,Boyoung Joung
BACKGROUND AND AIMS Artificial intelligence (AI) algorithms in 12-lead electrocardiogram (ECG) provides promising age prediction methods. This study investigated whether the discrepancy between ECG-derived AI-predicted age (AI-ECG age) and chronological age, termed electrocardiographic aging (ECG aging), is associated with atrial fibrillation (AF) risk. METHODS An AI-ECG age prediction model was developed
-
Data science from EuroHeart: a job in hand. Eur. Heart J. (IF 37.6) Pub Date : 2024-11-29 Adam Timmis
-
Thoracic aortic disease: why sex matters. Eur. Heart J. (IF 37.6) Pub Date : 2024-11-28 Julia Dumfarth,Simone Gasser,Michael Grimm
-
Handle with care, proceed with caution: do frail patients presenting with acute coronary syndrome benefit from revascularization? Eur. Heart J. (IF 37.6) Pub Date : 2024-11-28 Angelo Oliva,Roxana Mehran
-
Acetylation alchemy: how Nat10 shapes vascular health. Eur. Heart J. (IF 37.6) Pub Date : 2024-11-28 Timothy Warwick,Leo Kurian,Ralf P Brandes
-
Dissecting the effect of genetic variants on atherosclerosis: integrating bulk and single-cell transcriptomics. Eur. Heart J. (IF 37.6) Pub Date : 2024-11-28 Elisa Duregotti,Manuel Mayr
-
Pregnancy-related aortic pathology: where do we go from here? Eur. Heart J. (IF 37.6) Pub Date : 2024-11-28 Johanna A van der Zande,Mark R Johnson,Jolien W Roos-Hesselink
-
Myocardial infarction and low ambient temperature: does presence or absence of stenoses make a difference? Eur. Heart J. (IF 37.6) Pub Date : 2024-11-28 Magnus Bäck,Robin Hofmann
-
Weekly Journal Scan: Three is better than one for long-term risk prediction in healthy women. Eur. Heart J. (IF 37.6) Pub Date : 2024-11-28 Leonarda Galiuto,Giovanna Liuzzo
-
What's new in heart failure? November 2024 Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-11-28 Mert Tokcan, Julian Hoevelmann, Philipp Markwirth, Insa Emrich, Bernhard Haring
Click on the article title to read more.
-
Associations of iron deficiency with cardiac function, congestion, exercise capacity and prognosis in heart failure Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-11-28 Nicolò De Biase, Lavinia Del Punta, Wouter L'Hoyes, Pierpaolo Pellicori, John G.F. Cleland, Gabriele Masini, Luna Gargani, Sara Moura‐Ferreira, Sarah Hoedemakers, Valerio Di Fiore, Lieven Herbots, Jan Stassen, Alessandro Mengozzi, Silvia Armenia, Stefano Taddei, Stefano Masi, Jan Verwerft, Nicola Riccardo Pugliese
-
Ablation of persistent atrial fibrillation: lessons learnt from the CAPLA trial. Eur. Heart J. (IF 37.6) Pub Date : 2024-11-27 Jayanthi N Koneru,Kenneth A Ellenbogen
-
Enhanced Parkin-mediated mitophagy mitigates adverse left ventricular remodelling after myocardial infarction: role of PR-364 Eur. Heart J. (IF 37.6) Pub Date : 2024-11-27 Lizhuo Ai, Juliana de Freitas Germano, Chengqun Huang, Marianne Aniag, Savannah Sawaged, Jon Sin, Reetu Thakur, Deepika Rai, Christopher Rainville, David E Sterner, Yang Song, Honit Piplani, Suresh Kumar, Tauseef R Butt, Robert M Mentzer, Aleksandr Stotland, Roberta A Gottlieb, Jennifer E Van Eyk
Background and Aims Almost 30% of survivors of myocardial infarction (MI) develop heart failure (HF), in part due to damage caused by the accumulation of dysfunctional mitochondria. Organelle quality control through Parkin-mediated mitochondrial autophagy (mitophagy) is known to play a role in mediating protection against HF damage post-ischaemic injury and remodelling of the subsequent deteriorated
-
Percutaneous vs. surgical revascularization of non-ST-segment elevation myocardial infarction with multivessel disease: the SWEDEHEART registry. Eur. Heart J. (IF 37.6) Pub Date : 2024-11-27 Elmir Omerovic,Truls Råmunddal,Petur Petursson,Oskar Angerås,Araz Rawshani,Sandeep Jha,Kristofer Skoglund,Moman A Mohammad,Jonas Persson,Joakim Alfredsson,Robin Hofmann,Tomas Jernberg,Ole Fröbert,Anders Jeppsson,Emma C Hansson,Göran Dellgren,David Erlinge,Björn Redfors
BACKGROUND AND AIMS The long-term outcomes of percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel disease remain debated. METHODS The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry was
-
Neutrophil CRACR2A Promotes Neutrophil Recruitment in Sterile Inflammation and Ischemic Stroke. Circulation (IF 35.5) Pub Date : 2024-11-27 Jingu Lee,Brett Balzraine,Alexis Schweizer,Vasilisa Kuzmanova,Yousang Gwack,Babak Razani,Jin-Moo Lee,Deane F Mosher,Jaehyung Cho
BACKGROUND Ca2+ release-activated Ca2+ channel regulator 2A (CRACR2A) has been linked to immunodeficiency attributable to T-cell dysfunction in humans. We discovered that neutrophil CRACR2A promotes neutrophil adhesive and migratory functions by facilitating Ca2+ mobilization and β2 integrin activation. METHODS Myeloid-specific cracr2a conditional knockout mice and intravital microscopy were used to
-
New cardiovascular biomarkers in patients with advanced cancer – A prospective study comparing MR‐proADM, MR‐proANP, copeptin, high‐sensitivity troponin T and NT‐proBNP Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-11-27 Markus S. Anker, Laura C. Lück, Muhammad Shahzeb Khan, Jan Porthun, Sara Hadzibegovic, Alessia Lena, Ursula Wilkenshoff, Pia Weinländer, Ruben Evertz, Matthias Totzeck, Amir A. Mahabadi, Tienush Rassaf, Stefan D. Anker, Lars Bullinger, Ulrich Keller, Mahir Karakas, Ulf Landmesser, Javed Butler, Stephan von Haehling
-
Considerations on biological age‐related therapeutic intensity. Less numbers, more biology Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-11-27 Bernhard Haring, Michael Böhm
Click on the article title to read more.
-
Mesenchymal precursor cells reduce mortality and major morbidity in ischaemic heart failure with inflammation: DREAM‐HF Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-11-27 Emerson C. Perin, Kenneth M. Borow, Timothy D. Henry, Margaret Jenkins, Olga Rutman, Jack Hayes, Christopher W. James, Eric Rose, Hicham Skali, Silviu Itescu, Barry Greenberg
-
Relevance of residual tricuspid regurgitation for right ventricular reverse remodelling after tricuspid valve intervention in patients with severe tricuspid regurgitation and right‐sided heart failure Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-11-27 Ludwig T. Weckbach, Lukas Stolz, Philipp M. Doldi, Hannah Glaser, Cecilia Ennin, Michael Kothieringer, Thomas J. Stocker, Michael Näbauer, Mohammad Kassar, Sara Bombace, Karl‐Patrik Kresoja, Philipp Lurz, Fabien Praz, Holger Thiele, Volker Rudolph, Steffen Massberg, Jörg Hausleiter
-
Discontinuation and reinitiation of mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-11-27 Laura Landucci, Ulrika Ljung Faxén, Lina Benson, Ulf Dahlström, Juan J. Carrero, Gianluigi Savarese, Lars H. Lund
-
Reply to ‘Malnutrition and severe heart failure in real‐world study settings’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-11-27 Matteo Pagnesi, Marco Metra
Click on the article title to read more.
-
Social Bonds Retain Oxytocin-Mediated Brain-Liver Axis to Retard Atherosclerosis. Circ. Res. (IF 16.5) Pub Date : 2024-11-27 Seien Ko,Atsushi Anzai,Xueyuan Liu,Kenichiro Kinouchi,Kazuhiro Yamanoi,Takuto Torimitsu,Genki Ichihara,Hiroki Kitakata,Kohsuke Shirakawa,Yoshinori Katsumata,Jin Endo,Kaori Hayashi,Masahide Yoshida,Katsuhiko Nishimori,Kenji F Tanaka,Tatsushi Onaka,Motoaki Sano,Masaki Ieda
BACKGROUNDS Social interaction with others is essential to life. Although social isolation and loneliness have been implicated as increased risks of cardiometabolic and cardiovascular diseases and all-cause mortality, the cellular and molecular mechanisms by which social connection maintains cardiometabolic and cardiovascular health remain largely unresolved. METHODS To investigate how social connection